EGFR-mutated NSCLC (Disorder)

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Molecular Partners
Molecular PartnersSchlieren-Zurich, Switzerland
1 program
1
MP0250 DARPin® drug candidate, OsimertinibPhase 1Small Molecule1 trial
Active Trials
NCT03418532Terminated8Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Molecular PartnersMP0250 DARPin® drug candidate, Osimertinib

Clinical Trials (1)

Total enrollment: 8 patients across 1 trials

NCT03418532Molecular PartnersMP0250 DARPin® drug candidate, Osimertinib

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Start: Mar 2018Est. completion: Apr 20208 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)